Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 5/20 | 0.60 |
| ▸ | LPAR3 | Q9UBY5 | 5/20 | 0.60 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.58 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.58 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.58 |
| ▸ | MME | P08473 | 1/20 | 0.55 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.53 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5360200 | 1.00 | LPAR1 (0.60) | LPAR1LPAR3FFAR1FFAR4PLA2G2A | |
| SCHEMBL5351186 | 1.00 | LPAR1 (0.60) | LPAR1LPAR3FFAR1FFAR4PLA2G2A | |
| SCHEMBL5360192 | 1.00 | LPAR1 (0.60) | LPAR1LPAR3FFAR1FFAR4PLA2G2A | |
| SCHEMBL4312200 | 1.00 | LPAR1 (0.60) | LPAR1LPAR3FFAR1FFAR4PLA2G2A | |
| SCHEMBL5351183 | 1.00 | LPAR1 (0.60) | LPAR1LPAR3FFAR1FFAR4PLA2G2A | |
| SCHEMBL5353206 | 0.93 | LPAR3 (0.61) | LPAR1LPAR3FFAR1FFAR4PLA2G2A | |
| SCHEMBL5353213 | 0.93 | LPAR3 (0.61) | LPAR1LPAR3FFAR1FFAR4PLA2G2A | |
| SCHEMBL5355425 | 0.91 | LPAR3 (0.55) | LPAR1LPAR3PLA2G2AMME | |
| SCHEMBL5355431 | 0.91 | LPAR3 (0.55) | LPAR1LPAR3PLA2G2AMME | |
| SCHEMBL5356487 | 0.91 | LPAR3 (0.57) | LPAR1LPAR3FFAR1FFAR4PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025217379-A1 | DRUG TREATMENT FOR MACULAR DEGENERATION | UNIVERSITY OF ROCHESTER (US) | 2025-10-16 | — | — | WO | claimed |
| US-20240052352-A1 | COMPOSITIONS AND METHODS FOR CHARACTERIZING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH MULTIPLE ORGAN FAILURE | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2024-02-15 | — | — | US | claimed |
| WO-2022178407-A1 | COMPOSITIONS AND METHODS FOR CHARACTERIZING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH MULTIPLE ORGAN FAILURE | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2022-08-25 | — | — | WO | claimed |
| WO-2025217379-A1 | DRUG TREATMENT FOR MACULAR DEGENERATION | UNIVERSITY OF ROCHESTER (US) | 2025-10-16 | — | — | WO | disclosed |
| CN-120053454-A | Use of Darapladib in preparing medicine for treating osteoporosis | 浙江大学 | 2025-05-30 | — | — | CN | disclosed |
| US-20230285292-A1 | COMPOSITIONS AND METHODS OF USING A PLA2-RESPONSIVE DRUG DELIVERY SYSTEM | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2023-09-14 | — | — | US | disclosed |
| CN-115379836-A | Early management and prevention of sepsis and sepsis-like syndrome | 奥菲瑞克斯公司 | 2022-11-22 | — | — | CN | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-10877035-B2 | Advanced drug development and manufacturing | ICAGEN, LLC (US) | 2020-12-29 | — | — | US | disclosed |
| US-20150309021-A1 | Advanced Drug Development and Manufacturing | LOS ALAMOS NATIONAL SECURITY, LLC | 2015-10-29 | — | — | US | disclosed |
| EP-2511844-B1 | X-ray microscope | XRPRO SCIENCES INC (US) | 2015-08-12 | — | — | EP | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
| EP-1966169-A2 | COMPOSITIONS AND METHODS FOR THE INHIBITION OF PHOSPHOLIPASE A2 | Immupharma France SA (FR) | 2008-09-10 | — | — | EP | disclosed |
| US-20080031951-A1 | Compositions and methods for the inhibition of phospholipase A2 | IMMUPHARMA FRANCE SA (FR) | 2008-02-07 | — | — | US | disclosed |
| US-7253194-B2 | Compounds and inhibitors of phospholipases | THE UNIVERSITY OF QUEENSLAND (AU) | 2007-08-07 | — | — | US | disclosed |
| WO-2007074169-A2 | COMPOSITIONS AND METHODS FOR THE INHIBITION OF PHOSPHOLIPASE A2 | IMMUPHARMA FRANCE SA (FR) | 2007-07-05 | — | — | WO | disclosed |
| EP-1309552-A4 | COMPOUNDS AND INHIBITORS OF PHOSPHOLIPASES | UNIV QUEENSLAND (AU) | 2005-07-20 | — | — | EP | disclosed |
| US-20040033995-A1 | Compounds and inhibitors of phospholipases | QUEENSLAND, THE UNIVERSITY OF (AU) | 2004-02-19 | — | — | US | disclosed |
| EP-1309552-A1 | COMPOUNDS AND INHIBITORS OF PHOSPHOLIPASES | THE UNIVERSITY OF QUEENSLAND (AU) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002008189-A1 | COMPOUNDS AND INHIBITORS OF PHOSPHOLIPASES | THE UNIVERSITY OF QUEENSLAND (AU) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080031951-A1 | Compositions and methods for the inhibition of phospholipase A2 | PLA2G1B, PLA2G4A, PLA2G12A | LPAR1 155/4885LPAR3 88/4885FFAR1 1544/4885 |
| US-20040033995-A1 | Compounds and inhibitors of phospholipases | PLA2G4C, PLA2G4B, PLA2G4A | LPAR1 42/4885LPAR3 36/4885FFAR1 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.